These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Clinical effects and pharmacokinetics of different dosage schedules of adriamycin. Creasey WA; McIntosh LS; Brescia T; Odujinrin O; Aspnes GT; Murray E; Marsh JC Cancer Res; 1976 Jan; 36(1):216-21. PubMed ID: 942583 [TBL] [Abstract][Full Text] [Related]
24. [Phase II study of epirubicin in inoperable or recurrent gastric cancer]. Sakata Y; Yoshida Y Gan To Kagaku Ryoho; 1986 May; 13(5):1887-92. PubMed ID: 3458431 [TBL] [Abstract][Full Text] [Related]
25. [Clinical and pathological evaluations of methotrexate, vinblastine, adriamycin and cisplatin (M-VAC) chemotherapy for advanced urothelial cancers]. Takenaka A; Gotoh A; Hara I; Gohji K; Ogawa T; Arakawa S; Matsumoto O; Kamidono S; Hamami G; Itani A Gan To Kagaku Ryoho; 1990 Sep; 17(9):1909-15. PubMed ID: 2393308 [TBL] [Abstract][Full Text] [Related]
26. [Combined chemoendocrine therapy using adriamycin, cyclophosphamide and high dose toremifene in patients with recurrent breast cancer]. Wada N; Kobayashi H; Oka S; Ando J; Tamura H Gan To Kagaku Ryoho; 2002 Nov; 29(11):1935-42. PubMed ID: 12465393 [TBL] [Abstract][Full Text] [Related]
27. Phase I clinical trial: pharmacokinetics of a novel anthracycline, DA-125 and metabolites. Single dose study. Roh JK; Rha SY; Lee CI; Lee KH; Lee JJ; Shim HJ; Lee SD; Kim WB; Yang J; Kim SH; Lee MG Int J Clin Pharmacol Ther; 1998 Jun; 36(6):312-9. PubMed ID: 9660038 [TBL] [Abstract][Full Text] [Related]
28. [A phase II study of epirubicin in malignant lymphoma]. Masaoka T; Shibata H; Sampi K; Hirota Y; Yoshida Y; Chiba Y; Shirakawa S; Kobayashi T; Toki H; Tamura K Gan To Kagaku Ryoho; 1986 Aug; 13(8):2606-11. PubMed ID: 3461747 [TBL] [Abstract][Full Text] [Related]
29. Ftorafur, adriamycin and mitomycin C (FAM II) for extensive bronchogenic adenocarcinoma and large cell carcinoma. Salvati F; Cruciani AR; De Marinis A; Nunziati F; Portalone L Jpn J Clin Oncol; 1984 Mar; 14(1):3-6. PubMed ID: 6323790 [TBL] [Abstract][Full Text] [Related]
30. Doxorubicin and paclitaxel, a highly active combination in the treatment of metastatic breast cancer. Dombernowsky P; Gehl J; Boesgaard M; Paaske T; Jensen BV Semin Oncol; 1996 Oct; 23(5 Suppl 11):23-7. PubMed ID: 8893895 [TBL] [Abstract][Full Text] [Related]
31. Adriamycin in the treatment of childhood solid tumors. A Southwest Oncology Group study. Ragab AH; Sutow WW; Komp DM; Starling KA; Lyon GM; George S Cancer; 1975 Nov; 36(5):1567-76. PubMed ID: 1192348 [TBL] [Abstract][Full Text] [Related]
32. [Combination chemotherapy using cyclophosphamide, adriamycin, and cisplatin in recurrent or advanced endometrial cancer--a preliminary report]. Baba S; Kashimura M; Shinohara M; Kusano S; Sasayama T; Hamasaki K Gan No Rinsho; 1989 Feb; 35(3):371-7. PubMed ID: 2926985 [TBL] [Abstract][Full Text] [Related]
33. [Clinical usefulness of ondansetron hydrochloride for nausea and vomiting during repeated courses of chemotherapy for malignant lymphoma--impact of prognosis announcement on anti-emetic effect and evaluation of patient perception of chemotherapy-associated adverse events]. Kodama F; Mohri H; Motomura S; Fukawa H; Tanabe J; Koharasawa H; Kanamori H; Hashimoto Y; Harano H; Sakai R; Tomita N; Fujimaki K; Takemura S; Hattori M Gan To Kagaku Ryoho; 2002 Feb; 29(2):273-9. PubMed ID: 11865634 [TBL] [Abstract][Full Text] [Related]
34. Pharmacokinetics of liposomal doxorubicin (TLC-D99; Myocet) in patients with solid tumors: an open-label, single-dose study. Mross K; Niemann B; Massing U; Drevs J; Unger C; Bhamra R; Swenson CE Cancer Chemother Pharmacol; 2004 Dec; 54(6):514-24. PubMed ID: 15322827 [TBL] [Abstract][Full Text] [Related]
35. Adriamycin given as a weekly schedule without a loading course: clinically effective with reduced incidence of cardiotoxicity. Chlebowski RT; Paroly WS; Pugh RP; Hueser J; Jacobs EM; Pajak TF; Bateman JR Cancer Treat Rep; 1980 Jan; 64(1):47-51. PubMed ID: 7379058 [TBL] [Abstract][Full Text] [Related]
36. [Is the use of adriamycin (doxorubicin) limited by its cardiotoxicity?]. Reinhardt D; Hofmann V; Martz G Schweiz Med Wochenschr; 1985 Apr; 115(16):557-61. PubMed ID: 4001904 [TBL] [Abstract][Full Text] [Related]
37. Phase I clinical trial of a new anthracycline: 4'-o-tetrahydropyranyl adriamycin. Ogawa M; Miyamoto H; Inigaki J; Horikoshi N; Ezaki K; Inoue K; Ikeda K; Usui N; Nakada H Invest New Drugs; 1983; 1(2):169-72. PubMed ID: 6678865 [TBL] [Abstract][Full Text] [Related]
38. [Adriamycin, cisplatin, and etoposide combination chemotherapy for small cell lung cancer]. Irino S; Fujita J; Yamaji Y; Futami H; Hashimoto Y; Bungo M; Iuchi Y; Kamei M; Nakamura H; Hata Y Gan To Kagaku Ryoho; 1989 Jun; 16(6):2263-7. PubMed ID: 2544150 [TBL] [Abstract][Full Text] [Related]
39. Doxorubicin in disseminated osteosarcoma. Cores EP; Holland JF; Wang JJ; Sinks LF JAMA; 1972 Sep; 221(10):1132-8. PubMed ID: 4512088 [No Abstract] [Full Text] [Related]